With new gene sequencing panels, investigators made firm or possible diagnoses in almost one-third of undiagnosed autoinflammation and vasculitis cases.
The announcement comes three weeks after Interleukin said it was laying off 63 percent of its workforce and suspending sales of a controversial genetic test.
The decisions are part of the company's restructuring efforts after it was unable to extend deferral of its debt payment with its senior lender.
In Genome Biology this week: parainflammation found in some cancers, recurrent copy number changes affecting metabolic genes in cancer, and more.
In blood samples from infected individuals, a seven-gene signature apparently distinguishes between bacterial and viral culprits, a distinction important to antibiotic use.
The company's approach investigates the utility of high-density lipoproteins as molecular markers for multiple diseases, starting with cardiovascular.
The genetic testing firm is developing a plan to drive market adoption of its PerioPredict test for inflammation-related genes.
The FDA considers Interleukin Genetics' PerioPredict test and the DNA-CardioCheck test to be medical devices.
Researchers link personality traits to the expression of certain inflammation-related genes.
The project will include the development of mass spec tools for studying systems-level protein-protein interactions.
New Mexico is re-doing its proposed science education standards after criticism, the Associated Press reports.
Agbio executives say gene editing will speed up breeding efforts, according to the Wall Street Journal.
La Trobe University's Jenny Graves has won the $250,000 Prime Minister's Prize for Science, the Guardian reports.
In Cell this week: post-treatment changes to melanoma genome, multi-omics analysis of muscle-invasive bladder cancer, and more.